Large scale single-cell gene rearrangement detection with a microfluidic device
利用微流控装置进行大规模单细胞基因重排检测
基本信息
- 批准号:10468561
- 负责人:
- 金额:$ 32.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAdult Acute Myeloblastic LeukemiaAlternative SplicingAntibodiesBenchmarkingBiological AssayBone MarrowCell LineCell fusionCellsCessation of lifeChemoresistanceChromosome abnormalityClinicalComplementary DNAConduct Clinical TrialsCytogenetic AnalysisCytogeneticsDataData SetDetectionDiagnosisDiagnosticDiseaseDrug resistanceFlow CytometryGene ExpressionGene RearrangementGeneticGenomicsGoalsLengthLeukemic CellMalignant NeoplasmsMeasuresMessenger RNAMetaphaseMicrofluidic MicrochipsMicrofluidicsMolecularNamesOutcomePatientsPharmaceutical PreparationsPlayPrognosisRelapseReportingResearch PersonnelResolutionRoleSamplingSelection for TreatmentsSensitivity and SpecificitySpliced GenesSurvival RateTechniquesTechnologyacute myeloid leukemia celladult leukemiabasebioinformatics pipelinechemotherapycomputational pipelinesdroplet sequencingdrug relapsefusion geneimprovedleukemia relapseleukemia treatmentnanoporenew technologynext generationrisk stratificationsingle-cell RNA sequencingsurvivintherapeutic targettranscriptome sequencingtreatment response
项目摘要
Acute myeloid leukemia (AML) contributes to 32% of all adult leukemia and
remains one of the most clinically devastating cancers. Currently, AML diagnosis, risk
stratification and treatment selection are mainly based on cytogenetic abnormalities,
which suffers from low sensitivity and low resolution. To overcome this technical hurdle,
we propose to use single-cell RNAseq with microfluidic devices to generate a molecular
version of AML cytogenetic profile including all mRNA abnormalities from a large
number of leukemia cells, a technique we have named S-CytoSeq. This molecular S-
CytoSeq profiling provides fusion genes (FG) and alternative splicing (AS) profiles at
single-cell resolution and will have a significant clinical impact on AML treatment. The
ultimate translational goal is to replace conventional cytogenetics with S-CytoSeq.
急性髓性白血病(AML)占所有成人白血病的32%,
仍然是临床上最具破坏性的癌症之一。目前,AML诊断,风险
分层和治疗选择主要基于细胞遗传学异常,
其具有低灵敏度和低分辨率的缺点。为了克服这一技术障碍,
我们建议使用单细胞RNAseq和微流体装置来产生分子
AML细胞遗传学谱的一个版本,包括来自大细胞的所有mRNA异常。
白血病细胞的数量,我们将这项技术命名为S-CytoSeq。这个分子S-
CytoSeq分析提供融合基因(FG)和可变剪接(AS)谱,
单细胞分辨率,并将对AML治疗产生重大临床影响。的
最终的转化目标是用S-CytoSeq取代常规的细胞遗传学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Zhong其他文献
John Zhong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Zhong', 18)}}的其他基金
Large scale single-cell gene rearrangement detection with a microfluidic device
利用微流控装置进行大规模单细胞基因重排检测
- 批准号:
10031278 - 财政年份:2020
- 资助金额:
$ 32.37万 - 项目类别:
Large scale single-cell gene rearrangement detection with a microfluidic device
利用微流控装置进行大规模单细胞基因重排检测
- 批准号:
10737781 - 财政年份:2020
- 资助金额:
$ 32.37万 - 项目类别:
Large scale single-cell gene rearrangement detection with a microfluidic device
利用微流控装置进行大规模单细胞基因重排检测
- 批准号:
10454909 - 财政年份:2020
- 资助金额:
$ 32.37万 - 项目类别:
Large scale single-cell gene rearrangement detection with a microfluidic device
利用微流控装置进行大规模单细胞基因重排检测
- 批准号:
10202529 - 财政年份:2020
- 资助金额:
$ 32.37万 - 项目类别:
Supplement: Large scale single-cell gene rearrangement detection with a microfluidic device
补充:利用微流控装置进行大规模单细胞基因重排检测
- 批准号:
10522287 - 财政年份:2020
- 资助金额:
$ 32.37万 - 项目类别:
Molecular Characteristics of Treatment-resistant High-risk Neuroblastoma
难治性高危神经母细胞瘤的分子特征
- 批准号:
10470672 - 财政年份:2016
- 资助金额:
$ 32.37万 - 项目类别:
Molecular Characteristics of Treatment-resistant High-risk Neuroblastoma
难治性高危神经母细胞瘤的分子特征
- 批准号:
9247150 - 财政年份:2016
- 资助金额:
$ 32.37万 - 项目类别:
Multi-phase Microfluidic Devices for Characterization of Circulating Tumor Cells
用于表征循环肿瘤细胞的多相微流体装置
- 批准号:
8658772 - 财政年份:2012
- 资助金额:
$ 32.37万 - 项目类别:
Multi-phase Microfluidic Devices for Characterization of Circulating Tumor Cells
用于表征循环肿瘤细胞的多相微流体装置
- 批准号:
8657926 - 财政年份:2012
- 资助金额:
$ 32.37万 - 项目类别:
Multi-phase Microfluidic Devices for Characterization of Circulating Tumor Cells
用于表征循环肿瘤细胞的多相微流体装置
- 批准号:
8843387 - 财政年份:2012
- 资助金额:
$ 32.37万 - 项目类别: